AVEO AVEO Pharmaceuticals, Inc.

-0.0359  -5%
Previous Close 0.79
Open 0.78
Price To book 17.84
Market Cap 82.67M
Shares 110,362,000
Volume 455,619
Short Ratio 3.84
Av. Daily Volume 618,353

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial due to be completed 2Q 2017.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
EGFR-mutated Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be completed June 2017. Futility analysis due mid-2017. Top-line data due 1Q 2018 (Poster session at ASCO June 4, 2017). Abstract TPS4600.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer

Latest News

  1. AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma
  2. AVEO Announces Appointment of Matthew Dallas as Chief Financial Officer
  3. AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer
  4. AVEO Oncology Announces Receipt of USPTO Notice of Allowance Related to AV-353
  5. AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected
  6. Today's Research Reports on Biotech Stocks to Watch: AVEO Pharmaceuticals and PharmAthene
  7. AVEO reports 1Q loss
  8. AVEO Reports First Quarter 2017 Financial Results and Provides Business Update
  9. AVEO Pharmaceuticals (AVEO) Down 17.4% Since Earnings Report: Can It Rebound?
  10. AVEO Announces Presentations at the 2017 ASCO Annual Meeting
  11. AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues
  12. AVEO Announces Milestone Payment from CANbridge for AV-203
  13. AVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
  14. GGP, CenturyLink Drop into Tuesday’s 52-Week Low Club
  15. AVEO Announces Pricing of $15.0 Million Public Offering of Common Stock
  16. AVEO Announces Proposed Offering of Common Stock
  17. AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
  18. AVEO Reports Full Year 2016 Financial Results and Provides Business Update
  19. AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC